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ABSTRACT: Photopharmacology relies on molecules that
change their biological activity upon irradiation. Many of
these are derived from known drugs by replacing their core
with an isosteric azobenzene photoswitch (azologization).
The question is how many of the known bioactive ligands
could be addressed in such a way. Here, we systematically
assess the space of molecules amenable to azologization from
databases of bioactive molecules (DrugBank, PDB,
CHEMBL) and the Cambridge Structural Database. Shape similarity scoring functions (3DAPfp) and analyses of dihedral
angles are employed to quantify the structural homology between a bioactive molecule and the cis or trans isomer of its
corresponding azolog (“azoster”) and assess which isomer is likely to be active. Our analysis suggests that a very large number of
bioactive ligands (>40 000) is amenable to azologization and that many new biological targets could be addressed with
photopharmacology. N-Aryl benzamides, 1,2-diarylethanes, and benzyl phenyl ethers are particularly suited for this approach,
while benzylanilines and sulfonamides appear to be less well-matched. On the basis of our analysis, the majority of azosters are
expected to be active in their trans form. The broad applicability of our approach is demonstrated with photoswitches that target
a nuclear hormone receptor (RAR) and a lipid processing enzyme (LTA4 hydrolase).
■ INTRODUCTION
Many biological targets can be modulated by small molecules,
which can be modiﬁed with a photoswitch to obtain optical
control over their function. This approach, termed photo-
pharmacology, has been successfully applied to ion channels,
receptors, enzymes, transporters, and elements of the
cytoskeleton.1−3 Many drugs and bioactive molecules possess
motifs that resemble azobenzenes; i.e., they feature two arenes
separated by a two-atom linker (Figure 1A). Substitution of
this linker with a diazene unit (−NN−) allows for the
incorporation of a photoswitch with minimal structural
perturbation of the pharmacophore. We call this approach
“azologization” and the corresponding isosteric molecules
“azosters”.4,5 Ideally, only one isomer of the azolog exhibits the
bioactivity of the parent drug, while the other is inactive. A
number of stilbenes,6−12 N-aryl benzamides,13,14 benzyl phenyl
ethers,15,16 and benzyl anilines17 have been successfully
azologed. Other types, such as 1,2-diaryl ethanes, biaryl
sulfonamides, N-alkyl benzylanilines, could also be amenable
to this approach (Figure 1B).
The success of azologization strategies to date raises the
question how many bioactive molecules could be put under
optical control in such way. To this end, we assessed the
suitability of known bioactive ligands for azologization by
virtual screening. Candidates from the PDB, ChEMBL, and
DrugBank databases were evaluated based on computed
structural homology (3DAPfp) and analysis of the dihedral
angles of a central four-atom linker (Figure 1C).18 This
analysis leads to the identiﬁcation of over 40 000 bioactive
molecules that should be amenable to azologization, many of
which open new target classes for photopharmacology.
■ RESULTS AND DISCUSSION
Identiﬁcation of Bioactive Azologs. To conﬁne our
search to molecules with known bioactivity, we turned to the
databases PDB ligand,19 DrugBank,20 and CHEMBL.21 PDB
ligand contains experimentally determined 3D coordinates of
molecules in their target-bound conformations, whereas
DrugBank and CHEMBL combine 2D data (SMILES strings)
with comprehensive drug target information. We also analyzed
the Cambridge Structural Database (CSD), the largest source
of small molecule single crystal X-ray structures.22 To identify
possible azologable compounds in these databases, we
considered all molecules with up to 50 non-hydrogen atoms
and selected those containing a pair of aromatic or
heteroaromatic ring systems separated by a two-atom linker
(e.g., −CHCH−, −CH2−CH2−, −CH2−NH−, −CONH−,
−CH2−O−, −CH2−S−, −SO2−NH−, and others). In total,
we identiﬁed more than 180 000 bioactive molecules that meet
these criteria (Table 1), the majority of which were N-aryl
benzamides (>60 000), benzyl phenyl ethers (>23 000), biaryl
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sulfonamides (>19 000), and benzyl anilines (>17 000). We
also found more than 7000 stilbenes. The 3D coordinates of
these molecules were either extracted from the databases (PDB
and CSD) or calculated with the 3D structure generator
CORINA (Drugbank and ChEMBL).
Analysis of PDB Ligands and CSD Structures. We ﬁrst
turned to the azologable PDB ligands because their target-
bound conformations are known and can be directly compared
to that of the respective cis or trans azologs. We also decided to
include the experimental structures from the CSD into this
analysis which are usually obtained in much higher resolution.
To assess which compounds and linker-types are best suited
for azologization, we compared the dihedral angles (ω) deﬁned
by the C−X−Y−C linkers (Figure 2). Molecules with ω-values
close to 180° correspond to trans-azologs, while ω-values close
to 0° match the angles in cis-azologs.
The majority of PDB/CSD structures had dihedral angles
close to 180° corresponding to the respective trans-azologs.
Figure 1. Azologization of bioactive molecules. (A) The structure of azobenzene in its trans-form and azosteric motifs found in bioactive molecules.
(B) Selected examples of azosters drawn from the literature. (C) Systematic mapping of the photopharmacology space.
Table 1. Overview of Databases
no. of cmpds as per top ﬁve linker types
database no. of cmpds no. of azologable cmpdsa −CO−NH− −NH−CH2− −SO2−NH− −O−CH2− −CHCH− no. of linker types
PDB ligand 1,272,030 2,027 603 356 152 236 72 44
CSD 764,008 9,081 1,056 331 654 515 1,303 277
DrugBank 7,133 340 91 54 44 40 16 33
ChEMBL 1,678,393 167,688 59,522 16,263 18,354 22,724 6,856 192
aIn each database, only unique molecule entries (after counterion removal) containing acyclic linkers were considered. See Experimental Section
for details.
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Figure 2. Dihedral angle analysis of PDB and CSD compounds with azologable linkers.
Figure 3. Scatter plots showing the 3D-shape similarities of potential azologable compounds toward their cis-azolog (vertical axis) and trans-azolog
(horizontal axis), for compounds from PDB (a) and CSD (b). 3D Shape similarities are reported as the city block distance (CBD) in the 3DAPfp,
with the lowest value indicating highest similarity. Scatter plots are shown for six highly populated linker groups and rest of the groups merged
together (−X−Y−). Each of the scatter plots is marked with the structure of respective linker type. Color scale shows the density of molecules. The
compounds further investigated in this study are highlighted on the scatter plots.
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For biaryl sulfonamides, benzyl anilines, and benzyl phenyl
ethers we observed that a considerable number of
representatives had dihedral angle values around 60°. Since
this gauche conﬁrmation neither ﬁts the geometry of trans- nor
cis-azologs, these compounds are likely less amenable to
azologization.
Next, we computationally generated cis- and trans-azologs
for all PDB/CSD structures identiﬁed in our screen using the
3D builder CORINA.23 We compared the shape similarity of
the parent compound to the computed cis- and trans-azologs
using the 3D atom pair ﬁngerprint 3DAPfp, which is a 16-
dimensional ﬁngerprint counting the number of atom pairs at
exponentially increasing distances in a molecule, and which
encodes molecular shape.18 3D structural homology between
parent drug and either azolog isomer was quantiﬁed using city
block distance (CBD) metric, which is the sum of the absolute
diﬀerences between the 16 pairs of bit values in the respective
3DAPfp ﬁngerprints, such that a low CBD3DAPfp value indicates
a high shape similarity between two molecules. We
subsequently analyzed the entire azolog space comparing the
CBD values of parent structures with the respective cis/trans
azologs. The results from the analysis were scatter plotted by
linker type and database (Figure 3) and are individually
discussed for the major compound classes below. In addition,
we investigated for each class whether the linker engages in
hydrogen bonding, which would be partially or fully lost upon
azologization. We arbitrarily selected 30 benzyl anilines, N-
alkyl benzyl anilines, N-aryl benzamides, and biaryl sulfona-
mides from the PDB ligands and analyzed the crystal structures
for potential target engagement (SI Table 1).
Azobenzenes. In addition to the azologable targets
analyzed above, PDB and CSD also contained a large number
of azobenzenes themselves. Of course, these compounds would
be the most straightforward photoswitches to use. In our
search for bioactive azobenzenes we found 14 molecules in
Drugbank, 45 in PDB, and 1602 in ChEMBL. Similar to the
analysis performed above, we analyzed their experimentally
determined 3D structures as reported in the PDB and CSD
compared the dihedral angles across the C−NN−C moiety
(Figure 2). The majority of the azobenzenes were trans
isomers with angles close to 180°, whereas a few examples of
cis-azobenzenes existed that had dihedral angles close to 0°
(examples: PDB 2H4B, 2M0Z, and 2CLX). None of the
diazene units appear to engage in hydrogen bonding, although
azobenzenes are protonated at this site under strongly acidic
conditions (the pKa of methyl orange is 3.4).
Stilbenes. Stilbenes provide the most obvious azologization
motif since the dihedral angles of trans-stilbenes match those
of trans-azobenzenes, while cis-stilbenes would be expected to
give cis-active azologs. However, surprisingly few cis-stilbenes
have been found in our analysis. Combretastatin A-4 is a
notable exception (Figure 3).
1,2-Diarylethanes. To the best of our knowledge, 1,2-
diarylethanes have not yet been azologed for use in
photopharmacology. Their dihedral angle analysis shows that
approximately 50% of the PDB ligands bind their biological
target with angles closely matching those of trans-azobenzenes.
Like stilbenes, they cannot engage in hydrogen bonding at the
linker region.
N-Aryl Benzamides. The most abundant azologization
motifs found are N-aryl benzamides. The dihedral angle and
3D structural homology analyses conﬁrm that these molecules
should be prime targets for azologization and are expected to
give trans-active compounds. Their linker amide can function
as hydrogen bond donor or acceptor. Azologization could
therefore lead to a loss of the bioactivity. However, amide
linkers are often employed in medicinal chemistry to connect
two fragments with an easily formed bond. Indeed, we found
that approximately one-third of carboxamide linkers (11/30)
do not engage in hydrogen bonding, increasing the chances
that the corresponding azolog has comparable potency to the
parent compound.
Benzyl Phenyl Ethers. Benzyl phenyl ethers have been
successfully employed on a few occasions. Our study suggests
that this linker class is highly amenable to azologization. The
majority of benzyl phenyl ethers possesses dihedral angles
around 180°, which primes them as potential trans-azologs. A
few benzyl phenyl ethers have gauche angles making them less
suitable for azologization. Only 2 of the 30 benzyl phenyl
ethers analyzed showed hydrogen bonding to the linker, which
is signiﬁcantly less compared to N-aryl benzamides or benzyl
anilines.
N-Benzyl Anilines. While benzyl anilines have been
successfully azologed previously, our analysis suggests that
only a few of these compounds have suitable dihedral angles. A
surprisingly large proportion of these compounds exhibit
Figure 4. Dihedral angle analysis of ChEMBL and DrugBank compounds with azologable linkers.
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gauche-like dihedral angles. Approximately one-third of
secondary amine linkers (11/30) and tertiary amine linkers
(11/30) show hydrogen bonding in the linker region, which is
signiﬁcantly less than in N-aryl benzamides but more than in
benzyl phenyl ethers.
Biaryl Sulfonamides. Our analysis suggests that biaryl
sulfonamides are generally challenging targets for azologiza-
tion. They almost exclusively exhibit gauche conformations in
their bioactive form and do not show a pronounced tendency
for structural overlap with either trans- or cis-azologs in our 3D
structural homology analysis. Roughly one-third of the biaryl
sulfonamide analyzed (11/30) also showed hydrogen bonding
in the linker region.
Analysis of Drugbank and ChEMBL. Next, we repeated
the analysis for Drugbank and ChEMBL using the computa-
tionally generated 3D structures (CORINA calculation). With
the exception of sulfonamides, all linker types overwhelmingly
showed preferred dihedral angles close to 180° (Figure 4).
The scatter plots show similar distributions to that of PDB
and CSD compounds, suggesting that the CBD values could
indeed be indicative of isomer activity and guide the choice of
compounds for azologization (Figure 5). We calibrated this
analysis with three known photoswitches, which had previously
been developed using an azologization strategy (Figure 6).
These include VU-415374, a positive allosteric modulator of
metabotropic glutamate receptor type 4, the ion channel
blocker fomocaine, and the microtubule inhibitor combretas-
tatin A-4. For VU-415374 and fomocaine, the 3D structure
overlay with the respective trans-azolog showed more overlap
and signiﬁcantly lower CBD scores compared to that of the cis-
azolog. For combretastatin A-4 we obtained the reversed result
and signiﬁcantly better overlap between parent drug and cis-
azolog. These results matched the experimental results and
demonstrate that low CBD scores give good predictions about
which isomer of an azolog is active.
Azologs and Their Biological Targets. From the analysis
above, we selected all molecules from ChEMBL, DrugBank,
and PDB having two-atom linkers with experimental or
predicted linker dihedral angle falling within the range 0−
20° (cis-azologization targets) or within the range 160−180°
(trans-azologization targets; Table 2).
We analyzed these hits according to biological targets. In
total, more than 1200 biological targets in the CHEMBL
database could be amenable to azologization. Multiple hits
were found for most, which increases the chances to ﬁnd a
useful photopharmaceutical. Strikingly, only a small fraction of
these biological targets has been previously addressed by
photopharmacology. For example, relatively few enzymes
found were put under photocontrol. Kinases present the
largest class of biological targets that were identiﬁed in our
screen (Figure 7). While some eﬀorts in optogenetics have
been geared toward the optical control of kinases, only a few
studies in photopharmacology have addressed them. Other
target classes that could beneﬁt from the spatiotemporal
resolution of photopharmacology include transcription factors,
GPCRs, ion channels, and transporters.
Optical Control of RARα Receptor. To demonstrate the
usefulness of our analysis, we synthesized and evaluated a
number of hits. To this end, we chose molecules that are easily
synthetically accessible and could modulate biological targets
that have not been previously addressed with photo-
pharmacology.
Figure 5. Scatter plots showing the 3D shape similarities of potential azologable compounds toward their cis-azolog (vertical axis) and trans-azolog
(horizontal axis), for compounds from PDB (a) and CSD (b). 3D Shape similarities are reported as the city block distance (CBD) in the 3DAPfp,
with lowest value indicating highest similarity. Scatter plots are shown for six highly populated linker groups and rest of the groups merged together
(−X−Y−). Each of the scatter plots is marked with the structure of respective linker type. Color scale shows the density of molecules. The
compounds further investigated in this study are highlighted on the scatter plots.
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Nuclear hormone receptors (NHRs) are hormone targeted
transcription factors which bind to DNA and regulate various
biological processes.24,25 Apart from the modulation of
transcription levels on a relatively slow time scale, several
NHRs are known to mediate rapid nongenomic eﬀects which
are thought to occur through protein−protein interactions.26
Nongenomic functions of NHRs include the regulation of
kinases, phosphatase, and ion channels.27 Optical control of
NHRs could enable the dissection between genomic and
nongenomic mechanisms with the resolution of single cells in
complex cellular networks.
Our computational screen for azologization motifs led to the
identiﬁcation of several hits for a number of nuclear hormone
receptors, including retinoic X receptor, retinoic acid receptor,
Figure 6. (a) Structures of previously reported azologable compounds. The two atom linkers which were replaced by the diazo group are
highlighted in red. (b) 3D-overlays of parent azologable compounds (gray) with corresponding trans-azologs (yellow). (c) 3D-overlays of parent
azologable compounds (gray) with corresponding cis-azologs (yellow).
Table 2. Azologable Compounds
no. of cmpds. as per top ﬁve linker types
database no. of azologable cmpds −CO−NH− −NH−CH2− −SO2−NH− −O−CH2− −CHCH-
PDB Ligand 949 577 37 5 117 70
DrugBank 281 91 54 32 40 16
ChEMBL 40,719 16,097 4,746 3,915 7,785 1,186
Figure 7. Heatmaps showing (a) number of unique ChEMBL compounds and (b) number of unique ChEMBL targets as a function of linker type
and protein target family. Only azologable compounds within the correct predicted dihedral angle windows having IC50 and EC50 values of <10 μM
(∼41 K compounds) were considered for this analysis.
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thyroid hormone receptor, peroxisome proliferator-activated
receptor, liver X receptor, and estrogen receptor. We decided
to synthesize the azolog of one of these compounds targeting
retinoic acid receptor α (RARα). The potent RARα agonist
Am80 is commercially available and widely used in biological
research. At the same time our screen suggests that Am80 is an
ideal target for azologization (3DAPfp CBD trans: 14; 3DAPfp
cis: 147; Figure 8 A). Interestingly, the azolog of Am80 was
already synthesized in 1989 and evaluated in SAR studies
(CHEMBL 13150).28 However, its potential for optical control
has never been evaluated, and the compound was exclusively
tested in its nonirradiated form. We resynthesized the azolog of
Am80, termed Azo80 (Figure 8B), using Baeyer-Mills
conditions with subsequent ester hydrolysis (Figure 8C).
Figure 8. Computational prediction, design, and synthesis of Azo80. (A) 3D overlays of parent azologable compounds (gray) with corresponding
cis- and trans- azologs (yellow) and 3DAPfp scores of 3D shape similarity comparison. (B) Design of Azo80 based on the azologization of the N-
aryl benzamides Am80. (C) Chemical synthesis of Azo80.
Figure 9. Photophysical and biological evaluation of Azo80. (A) The UV−vis spectrum of Azo80 in the dark-adapted (black, trans), 365 nm
adapted (gray, cis), and 460 nm adapted (blue, trans) photostationary states. (B) Reversible cycling between isomers with alternating illumination
at 365/460 nm. (C) Schematic depiction of RARα activation with a small molecule photoswitch leading to corepressor/coactivator exchange and
transcription of target genes (here: luciferase−luc). (D) Dose responses of Am80, cis-Azo80, and trans-Azo80 in a luminescent reporter cell line
after 22 h. Samples were run in duplicates and in two independent experiments. Error bars represent mean ± SD (E) Control and rescue
(reversibility) experiments. Samples were run in triplicates. Error bars represent SEM *** p < 0.001, n.s., not signiﬁcant, student’s t-test.
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Figure 10. Synthesis and isomerization of LTA4h-Photoswitch. (A) 3D-overlays of parent azologable compounds (gray) with corresponding cis-
and trans- azologs (yellow) and 3DAPfp scores of 3D shape similarity comparison. (B) Design of LTA4h-Photoswitch based on the azologization
of a benzyl phenyl ethers. (C) Chemical synthesis of LTA4h-Photoswitch.
Figure 11. Photophysical evaluation and LTA4-hydrolase peptidase assay with LTA4H-Photoswitch. (A, B) Enzymatic reactions catalyzed by
LTA4-hydrolase. (C) The UV−vis spectrum of LTA4H-Photoswitch in the dark-adapted (black, trans), 365 nm adapted (gray, cis), and 460 nm
adapted (blue, trans) photostationary states. (D) Reversible cycling between isomers with alternating illumination at 365/460 nm. (E) Schematic
depiction of L-alanine 4-nitroanilide cleavage by LTA4H (PDB: 2VJ8
34). (F) LTA4H peptidase assay with LTA4 h (1.1 μg) and L-alanine 4-
nitroanilide (1 mM) in the presence and absence of cis-LTA4H-Photoswitch at diﬀerent concentrations. Samples were irradiated with 460 nm light
after 4 min to yield trans-LTA4H-Photoswitch. The slope of 4-nitroaniline absorption (λ = 410 nm) was plotted. (G, H) Representative traces of
4-nitroaniline absorption (λ = 410 nm) before and after application of 460 nm light. Samples were run in triplicates. Error bars represent SEM ** p
< 0.01, n.s., not signiﬁcant, student’s t-test.
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The photophysical properties of Azo80 are similar to those
of a classical nonsubstituted azobenzene. Azo80 can be
eﬃciently switched between cis/trans using 365/460 nm light
and is bistable (Figure 9A,B). To test Azo80 for the ability to
photocontrol RARα, we used a reporter gene assay in which
the activation of RARα induces transcription of luciferase
(Figure 9C). Upon addition of luciferase substrate after 24 h
incubation, a luminescent signal proportional to luciferase
transcription and RARα activation was quantiﬁed. We were
pleased to ﬁnd that the EC50 of cis-Azo80 (1.6 × 10
−8 M) is
signiﬁcantly lower than that of trans-Azo80 (6.0 × 10−9 M)
(Figure 9D). In a subsequent control experiment (Figure 9E),
we demonstrated that light does not mediate or alter
transcription levels in the absence of Azo80, while reversible
optical control is achieved with Azo80. To demonstrate
reversibility, Azo80 was added to cells as 365 nm-adapted cis-
Azo80 and after 5 min the cells were illuminated with 460 nm
light for 2 min to reactivate Azo80. Similar levels of
transcription were observed in this rescue experiment
compared to the experiment with dark-adapted trans-Azo80.
The trans-activity of Azo80 is coherent with the computational
prediction, which suggested better 3D homology of Am80 with
its trans-azolog.
Optical Control of Leuktriene-A4 Hydrolase. Lipid
photopharmacology is a rapidly growing ﬁeld, and photo-
switchable lipids have enabled the control of a wide range of
biological pathways.29−31 In this context, the optical
modulation of lipid metabolic networks could provide
important insights. Our computational screen identiﬁed a
number of small molecules that target various lipid
metabolizing enzymes, including fatty acid amide hydrolases,
lipoxygenases, phospholipases, leukotriene hydrolases, lipid
kinases, and phosphorylases. Many of these enzymes could be
interesting targets for photopharmacology. We decided to
synthesize and test a photoswitchable inhibitor of the enzyme
Leukotriene A4 hydrolase (LTA4H). LTA4H is a dual enzyme
that functions both as a hydrolase and as aminopeptidase
(Figure 11).32 It catalyzes the conversion of LTA4 to LTB4 and
the degradation of chemoattractant tripeptide molecules.
Multiple inhibitors for LTA4H have been in development as
anti-inﬂammatory drugs.33 The CHEMBL database contained
several benzyl phenyl ether based LTA4H inhibitors, and we
chose a relatively potent candidate of this compound family
with straightforward synthesis for azologization (Figure 10).
The CBD values suggest that this inhibitor exhibits more
structural homology with its trans-azolog (3DAPfp CBD trans:
10; 3DAPfp cis: 81; Figure 10 A). LTA4h-Photoswitch was
synthesized from 4-phenylazophenol through Williamson ether
synthesis (Figure 10C).
We used a colorimetric LTA4H peptidase assay to evaluate
the potential of LTA4H-Photoswitch for the optical control of
LTA4H aminopeptidase activity using L-alanine 4-nitroanilide
which is converted to the strongly absorbing 4-nitroaniline (λ
= 410). This assay is most commonly used to screen for
LTA4H inhibitors. In good agreement with the computational
prediction, trans-LTA4H-Photoswitch was a more potent
inhibitor of LTA4H peptidase than the cis-isomer (Figure 11).
Azo80 and LTA4H-Photoswitch are two new photoswitches
obtained through the azologization of a N-aryl benzamide and
a benzyl phenyl ether which were identiﬁed through the
mapping of the photopharmacological azolog space in
CHEMBL. These examples demonstrate the utility of the
database for the development of bioactive photoswitches for
the modulation of new photopharmacological targets from two
diﬀerent azologization motifs.
Concluding Remarks. Our study sheds light on the scope
and limitations of azologization in photopharmacology. The
azolog space was found to be surprisingly large, comprising
more than 40 000 bioactive molecules, which modulate more
than 1200 biological targets. Relatively few of those have been
put under optical control to date. The identiﬁcation of
functional azologs for two completely diﬀerent new targets
classes (LTA4H and RARα) illustrates the usefulness of our
systematic approach.
3DAPfp shape similarity scores and analysis of dihedral
angles gave good predictions of the active isomer for the
examples explored and for the newly developed photoswitches
reported. These scores could be used to predict which isomer
is bioactive. Additional insights for the design and prediction
can often be drawn from crystal structures and structure
activity relationship studies.
Our results suggest that stilbenes, 1,2-diarylethanes, N-aryl
benzamides, and benzyl phenyl ethers are excellent candidates
for azologization. Benzylanilines and especially sulfonamides
appear to be less suited for this approach. The analysis of both
dihedral angles and shape similarity indicates that the vast
majority of azologs are likely to be more bioactive in their
trans-form. Usually cis-active photoswitches are more desirable
as they are inactive in the dark-adapted state and can be
activated with light. However, trans-active compounds can still
be highly useful (e.g., as tonic ion channel blockers) and
bistable photoswitches that can be easily kept in the inactive
cis-state. In addition, cis-stable azobenzene photoswitches are
emerging that could be adapted to photopharmacology.35
The large number of potential molecular targets (>1200)
that should be addressable with photopharmacology suggests
that this approach to optical control is very versatile. It should
be noted, however, that methods other than azologization
further increase the reach of photopharmacology. Many
photoswitches were designed through extension of the core
with azobenzenes instead of replacement (“azo-extension”
approach). An n-alkyl chain has been replaced with an
azobenzene in the optical control of glycerophospho- and
sphingolipids. In addition, photoswitches have been success-
fully installed in the backbone or side chain of biopolymers,
such as nucleic acids and peptides. While “azologization” is the
most straightforward design strategy, all existing strategies
complement each other to provide an exceptionally versatile
photopharmacological toolbox.
■ EXPERIMENTAL SECTION
Processing of Database and Azologs Generation.
DrugBank (version 5, https://www.drugbank.ca/), PDB
ligands (http://ligand-expo.rcsb.org/ld-download.html), and
ChEMBL (version 22, https://www.ebi.ac.uk/chembl/) data-
bases were downloaded in SDF format from the respective
database Web site in year 2017. CSD was copied from a
licensed CD to Dr. Jürg Hauser, University of Bern. Molecules
were processed using an in-house developed Java program
utilizing the JChem chemistry library from ChemAxon Pvt.
Ltd. (https://www.chemaxon.com/). Counter ions were
removed, valence errors were checked, and molecules were
ionized at pH 7.4. Molecules containing ≥6 and ≤50 heavy
atoms, ≤4 stereocenters, 1 Ar-(two atom linker)-Ar, and no
Ar-(diazo linker)-Ar were retained in the database. “Ar” stands
for aromatic carbon. The two atoms in linker are acyclic atoms
ACS Central Science Research Article
DOI: 10.1021/acscentsci.8b00881
ACS Cent. Sci. 2019, 5, 607−618
615
and may or may not be substituted. For each database,
duplicate molecules were removed based on unique smiles
comparisons. The resulting molecules in these processed
databases are considered as potential azologable compounds.
Afterward for each of the azologable molecules, Ar-(two atom
linker)-Ar was replaced by Ar-(diazo linker)-Ar, and
corresponding trans- and cis-azologs were generated. It should
be noted that, whenever the diﬀerence in number of atoms
between parent azologable molecules and corresponding
azologs were more than six atoms, the corresponding
molecules were not considered in the study. This was because
some of the two atom linkers in parent molecules were
substituted by large groups.
Similarity Calculation. For each drug and its two isomeric
azolog, we generated the lowest energy 3D conformer using
the CORINA program available from Molecular Networks Pvt.
Ltd. For the parent azologable compounds in PDB and CSD
databases experimental 3D coordinates were used. To compare
molecules, we used an in-house developed 3D atom pair
ﬁngerprint as a measure of overall shape similarity.36 For each
parent drug and its corresponding cis and trans azolog 3D atom
pair ﬁngerprints were computed, and similarities between them
were quantiﬁed using city block distance metric.
Chemical Synthesis. All reagents and solvents were
purchased from commercial sources (Sigma-Aldrich, TCI
Europe N.V., Strem Chemicals, etc.) and were used without
further puriﬁcation. Solvents were obtained from Fisher
Scientiﬁc. Reactions were monitored by TLC on precoated,
Merck Silica gel 60 F254 glass backed plates, and the
chromatograms were ﬁrst visualized by UV irradiation at λ =
254 nm. Flash silica gel chromatography was performed using
silica gel (SiO2, particle size 40−63 μm) purchased from
SiliCycle. NMR spectra were measured on a BRUKER Avance
III HD 400 (equipped with a CryoProbe). Multiplicities in the
following experimental procedures are abbreviated as follows: s
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet.
Proton chemical shifts are expressed in parts per million (ppm,
δ scale) and are referenced to the residual protium in the NMR
solvent (CDCl3 = 7.26; MeOD: δ = 3.31). Carbon chemical
shifts are expressed in ppm (δ scale) and are referenced to the
carbon resonance of the NMR solvent ((CDCl3: δ = 77.16;
MeOD: δ = 49.00). NOTE: Due to the trans/cis isomerization
of some compounds containing an azobenzene functionality,
more signals were observed in the 1H and 13C spectra than
would be expected for the pure trans-isomer. Only signals for
the major trans-isomer are reported.
Photophysical Evaluation. UV−vis spectra were re-
corded using a Varian Cary 50 Bio UV−visible spectropho-
tometer with Hellma SUPRASIL precision cuvettes (10 mm
light path). Switching was achieved using 365 or 460 nm LED
light sources. The LEDs were pointed directly into the top of
the sample cuvette. An initial spectrum was recorded (dark-
adapted state, black) and then again following illumination at λ
= 365 nm for 30 s (cis-adapted state, gray). A third spectrum
was recorded after irradiation at λ = 470 nm for 30 s (trans-
adapted state, blue).
Azo80. A solution of Oxone (378 mg, 0.615 mmol, 2.5
equiv) in water (2 mL) was added to a solution of 4-
aminobenzoate (37.2 mg, 0.246 mmol, 1.0 equiv) in CH2Cl2
(2 mL), and the biphasic mixture was stirred for 16 h at rt. The
organic layer was washed with 1 M HCl, sat. NaHCO3, water,
dried over sodium sulfate, ﬁltered, and concentrated in vacuo.
5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine (50.0
mg, 0.246 mmol, 1.0 equiv) and acetic acid (2.0 mL) were
added and stirred for 24 h at rt. Acetic acid was removed in
vacuo, and the residue was dissolved in CH2Cl2, washed with
sat. NaHCO3, water, dried over sodium sulfate, ﬁltered, and
concentrated in vacuo. The residue was dissolved in THF/
MeOH (2 mL/2 mL), treated with 1 M LiOH (1 mL), stirred
for 2 h at rt, and acidiﬁed with 2 M HCl. It was diluted with
EtOAc, washed with water, dried over sodium sulfate, ﬁltered,
and concentrated in vacuo. Puriﬁcation by ﬂash column
chromatography (CH2Cl2 + 1% AcOH) aﬀorded Azo80
(13.8 mg, 0.041 mmol, 17%) as an orange solid. A small
amount of methanol was added to obtain a more concentrated
solution for the 13C NMR measurement. 1H NMR (400 MHz,
CDCl3) δ 8.32−8.04 (m, 3H), 7.89 (d, J = 1.8 Hz, 1H), 7.86
(d, J = 7.7 Hz, 2H), 7.63 (dd, J = 8.5, 1.9 Hz, 1H), 7.40 (d, J =
8.5 Hz, 1H), 1.69 (s, 4H), 1.33 (s, 6H), 1.28 (s, 6H). 13C
NMR (100 MHz, CDCl3) δ 155.5, 150.7, 149.5, 146.2, 131.0,
127.6, 123.6, 123.4, 122.4, 118.5, 35.0, 34.9, 34.8, 34.6, 31.8,
31.7. HRMS: m/z calcd. for C21H23N2O2
− ([M + H]−):
335.1765, found: 335.1758.
LTA4H-Photoswitch. A solution of 1-(2-chloroethyl)-
pyrrolidine·HCl (51.4 mg, 0.30 mmol, 1.2 equiv), 4-phenyl-
azophenol (50.0 mg, 0.25 mmol, 1.0 equiv), and K2CO3 (104
mg, 0.76 mmol, 3.0 equiv) in DMF (3 mL) was stirred at 85
°C for 16 h. The solution was cooled, water was added, and
extracted with EtOAc. The combined organic phase was dried
over Na2SO4, and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography with CH2Cl2 → 10% MeOH in
CH2Cl2 yielded LTA4H-Photoswitch (38.6 mg, 0.13 mmol,
52%) as an orange liquid. 1H NMR (400 MHz, MeOD): δ
7.93−7.81 (m, 4H), 7.55−7.39 (m, 3H), 7.11−7.04 (m, 2H),
4.19 (t, J = 5.6 Hz, 2H), 2.94 (t, J = 5.6 Hz, 2H), 2.68 (t, J =
6.6 Hz, 4H), 1.86−1.78 (m, 4H). 13C NMR (100 MHz,
MeOD): δ 162.8, 154.0, 148.3, 131.6, 130.2, 125.8, 123.5,
115.9, 67.9, 55.5, 24.2. HRMS: m/z calcd. for C18H22N3O ([M
+ H]+): 296.1757, found: 296.1757.
RARα Reporter Gene Assay. A cell-based human RARα
(NR1B1) driven luciferase reporter assay from INDIGO
Bioscience (State College, PA) was adapted and used for the
biological evaluation of Azo80. In brief, a 10 mM stock
solution of Am80 or Azo80 was diluted with the provided cell
screening medium to a ﬁnal concentration of 2.5 μM. A 4-fold
dilution series was prepared using this initial concentration and
cell screening medium. The dilutions were added to reporter
cells in white-bottom 96-well plates. For trans-Azo80, dilutions
were added in the dark and cells were incubated for 22 h in the
dark. For cis-Azo80, dilutions were irradiated at 365 nm for 3
min, and cells were incubated for 22 h in the presence of a 370
nm LED Cell Disco with light pulses for 75 ms/15 s. To
minimize variations in the dilutions, the same dilutions were
used for both experiments before and after irradiation. For the
rescue experiment, Azo80 was added to cells as 365 nm
adapted cis-Azo80 and cells were illuminated after 5 min with
460 nm light for 2 min to reactivate Azo80. After 22 h medium
was ejected, and the supplied luciferase detection reagents
were added and quantiﬁed using a BMG Labtech FLUOstar
Omega plate reader.
LTA4H-Peptidase Assay. Recombinant LTA4H was
purchased from Cayman Chemicals and stored at −80 °C.
LTA4H (1.1 μg) was incubated with L-alanine-p-nitroanilide (1
mM), in 50 mM HEPES (pH = 7.5), 100 mM KCl, 1 mg/mL
BSA, 1% DMSO in the presence and absence of LTA4H-
Photoswitch. LTA4H-Photoswitch was illuminated with 365
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nm light for 3 min before addition of L-alanine-p-nitroanilide,
and the reaction was initiated with LTA4H added last. The
absorption at 410 nm was recorded for 4 min. After 4 min a
460 nm LED was used to illuminate the sample in the cuvette,
and the absorption was recorded for 4 min under constant
illumination.
Safety Statement. No unexpected or unusually high safety
hazards were encountered in this line of research.
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(1) Hüll, K.; Morstein, J.; Trauner, D. In Vivo Photopharmacology.
Chem. Rev. 2018, 118, 10710−10747.
(2) Beharry, A. A.; Woolley, G. A. Azobenzene Photoswitches for
Biomolecules. Chem. Soc. Rev. 2011, 40, 4422−4437.
(3) Velema, W. A.; Szymanski, W.; Feringa, B. L. Photo-
pharmacology: Beyond Proof of Principle. J. Am. Chem. Soc. 2014,
136, 2178−2191.
(4) Broichhagen, J.; Frank, J. A.; Trauner, D. A Roadmap to Success
in Photopharmacology. Acc. Chem. Res. 2015, 48, 1947−1960.
(5) Schoenberger, M.; Damijonaitis, A.; Zhang, Z.; Nagel, D.;
Trauner, D. Development of a New Photochromic Ion Channel
Blocker via Azologization of Fomocaine. ACS Chem. Neurosci. 2014,
5, 514−518.
(6) Borowiak, M.; Nahaboo, W.; Reynders, M.; Nekolla, K.; Jalinot,
P.; Hasserodt, J.; Rehberg, M.; Delattre, M.; Zahler, S.; Vollmar, A.;
et al. Photoswitchable Inhibitors of Microtubule Dynamics Optically
Control Mitosis and Cell Death. Cell 2015, 162, 403−411.
(7) Engdahl, A. J.; Torres, E. A.; Lock, S. E.; Engdahl, T. B.; Mertz,
P. S.; Streu, C. N. Synthesis, Characterization, and Bioactivity of the
Photoisomerizable Tubulin Polymerization Inhibitor Azo-Combretas-
tatin A4. Org. Lett. 2015, 17, 4546−4549.
(8) Sheldon, E.; Dcona, M. M.; Lyons, C. E.; Hackett, J. C.;
Hartman, M. C. T. Photoswitchable Anticancer Activity via Trans −
Cis Isomerization of a Combretastatin A-4 Analog. Org. Biomol. Chem.
2016, 14, 40−49.
(9) Damijonaitis, A.; Broichhagen, J.; Urushima, T.; Hull, K.;
Nagpal, J.; Laprell, L.; Schonberger, M.; Woodmansee, D. H.; Rafiq,
A.; Sumser, M. P.; et al. AzoCholine Enables Optical Control of Alpha
7 Nicotinic Acetylcholine Receptors in Neural Networks. ACS Chem.
Neurosci. 2015, 6, 701−707.
(10) Broichhagen, J.; Jurastow, I.; Iwan, K.; Kummer, W.; Trauner,
D. Optical Control of Acetylcholinesterase with a Tacrine Switch.
Angew. Chem., Int. Ed. 2014, 53, 7657−7660.
(11) Rastogi, S. K.; Zhao, Z.; Barrett, S. L.; Shelton, S. D.; Zafferani,
M.; Anderson, H. E.; Blumenthal, M. O.; Jones, L. R.; Wang, L.; Li,
X.; et al. Photoresponsive Azo-Combretastatin A-4 Analogues. Eur. J.
Med. Chem. 2018, 143, 1−7.
(12) Ferreira, R.; Nilsson, J. R.; Solano, C.; Andreásson, J.; Grøtli,
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